MedTrace Logo

Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns

NCT07259668 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2026-01-22

No results posted yet for this study

Summary

This observational pilot study aims to establish criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS device in adult patients with burn injury. Participants will be prospectively enrolled into the treatment group and compared with a retrospectively selected control group. Each patient in the treatment group will undergo two hemoadsorption sessions, each lasting 6-12 hours, with a 24 hours interval between sessions. The procedures may be performed in combination with hemofiltration or hemodiafiltration at the investigator's discretion.

Conditions

  • Burns

Interventions

DEVICE

Efferon LPS

Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity. Two hemoadsorption procedures will be performed per patient, with a duration of 6-12 hours each and an interval of 24 hours between procedures. The procedures may be administered in combination with hemofiltration or hemodiafiltration, as determined by the investigator.

Sponsors & Collaborators

  • Efferon JSC

    lead INDUSTRY

Principal Investigators

  • Igor Samatov, PhD, MD · State Novosibirsk Regional Clinical Hospital

  • Alexander Mezhin, PhD, MD · State Novosibirsk Regional Clinical Hospital

  • Vladimir Kulabukhov, PhD, MD · NV Sklifosovsky Research Institute for Emergency Medicine

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-08
Primary Completion
2027-12-31
Completion
2028-03-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07259668 on ClinicalTrials.gov